/
ALXO
$2.20+$0.16 (+7.84%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$274.5M
135M shares
52-week range
$0.41 – $2.66
80% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.30%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-53.77
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.1M | $4.8M | $1.2M | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $1.9M | $4.4M | $1.1M | $0 | $0 | $0 | $0 | $0 |
| Gross profit | $187.0K | $436.0K | $107.0K | $0 | $0 | $0 | $0 | $0 |
| Gross margin | 9.0% | 9.1% | 9.1% | — | — | — | — | — |
| R&D | $11.3M | $16.3M | $29.0M | $60.2M | $98.4M | $141.8M | $116.4M | $77.0M |
| Operating income | −$13.7M | −$19.2M | −$43.7M | −$83.6M | −$127.4M | −$170.3M | −$142.5M | −$104.0M |
| EBITDA | −$13.3M | −$18.8M | −$43.5M | −$83.4M | −$122.8M | −$158.4M | −$132.2M | −$99.4M |
| Net income | −$13.7M | −$19.2M | −$45.7M | −$83.5M | −$123.5M | −$160.8M | −$134.8M | −$101.7M |
| Net margin | -664.3% | -401.2% | -3869.7% | — | — | — | — | — |
| EPS (diluted) | -0.63 | -0.88 | -1.28 | -2.07 | -3.03 | -3.74 | -2.58 | -1.90 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $5M | $-0.61 | $-0.67–$-0.55 | 3 |
| 2027 | $5M | $-0.58 | $-0.64–$-0.51 | 3 |
| 2028 | $55M | $-0.57 | $-0.80–$-0.34 | 6 |
| 2029 | $180M | $-0.65 | $-0.65–$-0.65 | 4 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$0.13
Price
$2.20
Implied downside
-94%
Peer comparison
ALX Oncology Holdings Inc. Common Stock
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
www.alxoncology.com- Employees
- 43
- IPO / List date
- Jul 17, 2020
- HQ
- SOUTH SAN FRANCISCO, CA
Held by traders on TradeandTell
No one on the platform currently holds ALXO.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 732,599 | $1.5M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded ALXO yet.
